Results 1 to 10 of about 23,180 (193)

Liposomal amphotericin B-the present. [PDF]

J Antimicrob Chemother, 2022
AbstractMost invasive fungal infections are opportunistic in nature but the epidemiology is constantly changing, with new risk groups being identified. Neutropenia is a classical risk factor for fungal infections, while critically ill patients in the ICU are now increasingly at risk of yeast and mould infections.
Maertens J, Pagano L, Azoulay E, Warris A.   +3 more
europepmc   +5 more sources

Liposomal amphotericin B-the past. [PDF]

J Antimicrob Chemother, 2022
Abstract The discovery of amphotericin B, a polyene antifungal compound, in the 1950s, and the formulation of this compound in a liposomal drug delivery system, has resulted in decades of use in systemic fungal infections. The use of liposomal amphotericin B formulation is referenced in many international guidelines for the treatment of ...
Brüggemann RJ, Jensen GM, Lass-Flörl C.   +2 more
europepmc   +5 more sources

Liposomal amphotericin B-the future. [PDF]

J Antimicrob Chemother, 2022
AbstractAdvances in medicine have led to a growing number of people with compromised or suppressed immune systems who are susceptible to invasive fungal infections. In particular, severe fungal infections are becoming increasingly common in ICUs, affecting people within and outside of traditional risk groups alike.
Hoenigl M, Lewis R, van de Veerdonk FL, Verweij PE, Cornely OA.   +4 more
europepmc   +8 more sources

Using single-dose liposomal amphotericin B for cryptococcal meningitis induction therapy: nurse pearls and practical perspectives [version 2; peer review: 2 approved] [PDF]

Wellcome Open Research
Background In Uganda where the burden of HIV-associated cryptococcal meningitis is high, conventional amphotericin B deoxycholate has been standard to manage patients with cryptococcal meningitis in research settings.
Richard Kwizera, Cynthia Ahimbisibwe, Jane Frances Ndyetukira, David B. Meya, Carol Namujju   +4 more
doaj   +2 more sources

Persistent dyselectrolytemia in a neonate induced by liposomal amphotericin B. A case report [PDF]

Frontiers in Pediatrics, 2023
BackgroundNephrotoxicity is the most frequent serious adverse effect associated with amphotericin B deoxycholate treatment, for this reason, in recent years it has been relegated from routine clinical practice and replaced by the new liposomal ...
Adrian Puertas Sanjuan, Carlos Javier Parramón-Teixidó, Susana Hernandez-Perez, Marie Antoinette Frick, Maria Jose Cabañas Poy   +4 more
doaj   +2 more sources

Successful ventilator weaning after aerosolized liposomal amphotericin B in persistent Candida glabrata colonization: a case report [PDF]

Frontiers in Medicine
BackgroundInvasive candidiasis and persistent fungal colonization of the airways are increasingly recognized as potential barriers to successful weaning from mechanical ventilation in critically ill patients.
Massimo Caracciolo, Simona Pellicano, Sarah Antonella Caracciolo, Maria Francesca Stagno, Antonino Ripepi, Selma Valerie Mammone, Nadia Pellicano, Stefano La Scala, Giuseppe Mazza, Giuseppe Neri   +9 more
doaj   +2 more sources

Primary treatment of chronic pulmonary aspergillosis with weekly liposomal amphotericin B: A case report from Uganda [PDF]

Medical Mycology Case Reports
Chronic pulmonary aspergillosis (CPA) treatment in Africa remains unexplored. We present a 23-year-old Ugandan male, previously treated thrice for pulmonary tuberculosis, developing CPA. Imaging showed lung fibrosis, bronchiectasis, and a fungal ball. He
Winnie Kibone, Felix Bongomin, David W. Denning, David B. Meya   +3 more
doaj   +2 more sources

Comparison of the Efficacies of Topical Liposomal Amphotericin B and Topical Clotrimazole in the Treatment of Pityriasis Versicolor [PDF]

Dermatology Practical & Conceptual
Introduction: Pityriasis versicolor (PV) often exhibits recurrence even despite treatment, and a standardized therapy with a complete cure rate remains elusive.
Mehdi Ghahartars, Hossein Hosseini, Malek Khedri, Maryam Sadat Sadati   +3 more
doaj   +2 more sources

Efficacy of combination therapy of amphotericin and posaconazole in treatment of mucormycosis

Journal of Applied Pharmaceutical Research, 2023
Background: Mucormycosis is an opportunistic systemic fungal infection which is debilitating caused by order Mucorales. The standard management of mucormycosis consists of aggressive debridement of the infected tissue and parenteral anti-fungal therapy ...
Sridhara S, Ramesh Sanappa, Nandini P, Gayatri Jayan, Gangadhara KS   +4 more
doaj   +1 more source

Efficacy of Systemic Treatment for Leishmania tropica Cutaneous Leishmaniasis

Acta Dermato-Venereologica, 2022
The effectiveness of systemic treatment for Leishmania tropica cutaneous leishmaniasis remains unclear. The purpose of the study is to evaluate the efficacy and safety of systemic treatments for L. tropica cutaneous leishmaniasis.
Michal Solomon, Shoshana Greenberger, Maya Milner, Felix Pavlotzky, Aviv Barzilai, Eli Schwartz, Noa Hadayer, Sharon Baum   +7 more
doaj   +1 more source